论文部分内容阅读
目的探讨来曲唑用于多囊卵巢综合征(PCOS)患者的促排卵临床效果。方法符合PCOS诊断的不孕患者262例分为两组,来曲唑(LE)组132例,5mg/d,克罗米芬(CC)组130例,100mg/d。用药时机:月经来潮或撤退性出血第4天起服用药物,连服5d;每组均同期纪录卵泡发育、排卵率、妊娠率、多胎妊娠率等指标。结果 LE促排卵治疗132例患者198个周期中183个周期有排卵,11个周期发生黄素化卵泡未破裂综合征(LUFS),未出现卵巢过度刺激综合征(OHSS),妊娠率19.2%。CC促排卵治疗130例患者193个周期中168个周期有排卵,22个周期发生LUFS,妊娠率15.0%。结论 LE用于PCOS患者,具有良好的排卵率,而妊娠率无显著差异,LE是否能替代CC作为一线的促排卵药还有待于临床进一步的研究。
Objective To investigate the clinical effect of letrozole on ovulation induction in patients with polycystic ovary syndrome (PCOS). Methods Two hundred and sixty-two infertile women diagnosed with PCOS were divided into two groups: 132 patients in letrozole group (LE), 5 mg / day and 130 patients in clomiphene citrate group (100 mg / d). Medication time: menstrual cramps or withdrawal bleeding from the 4th day medication, even for 5d; each group were the same period record follicular development, ovulation rate, pregnancy rate, multiple pregnancy rate and other indicators. Results In 132 patients with LE, ovulation took place in 183 cycles during 198 cycles, LUFS did not occur in 11 cycles, ovarian hyperstimulation syndrome (OHSS) did not occur, and the pregnancy rate was 19.2%. Ovulation treatment of ovulation in 130 patients ovulation in 168 cycles of 193 cycles, LUFS in 22 cycles, pregnancy rate of 15.0%. Conclusions LE was used in PCOS patients with good ovulation rate, but no significant difference in pregnancy rate. Whether LE can replace CC as first-line ovulation promoter remains to be further studied in clinic.